Close Menu

Cellular Dynamics International

The partners will offer drug discovery services based on human induced pluripotent stem cells and cells derived from these.

The companies will offer CDI's human induced pluripotent stem cell-derived tissue cells with Nanion's ion channel drug discovery and screening platform.

Under the terms of the deal, Stemcell will distribute Cellular Dynamics' iCell line of induced pluripotent stem cell products.

The Madison, Wisconsin-based firm, a subsidiary of Fujifilm, will supply iCell products to Roche for use in drug discovery.

SeouLin Bioscience will distribute the company's cell line products in the Republic of Korea, and provide first-level technical support for local customers.

The deal was completed on May 1, following the expiration of a tender offer in which Cellular Dynamics' shareholders tendered 90 percent of the company's common stock. 

The deal marries Cellular Dynamics' human cell line manufacturing with Fujifilm's recombinant peptide cell scaffolding offerings.

The increase in revenues was driven by stem cell banking contracts and sales of iCell Hepatocytes.

NEW YORK (GenomeWeb) – Cellular Dynamics International today reported that its third quarter revenues increased 44 percent year over year.

NEW YORK (GenomeWeb) – Cellular Dynamics International today announced a $1.2 million contract from the National Eye Institute to manufacture stem cells for use in the development of a new potential treatment for dry age-related macular degeneration.

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.